PMID- 34255538
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20220802
IS  - 2688-1535 (Electronic)
IS  - 2688-1527 (Print)
IS  - 2688-1527 (Linking)
VI  - 17
IP  - 8
DP  - 2021 Aug
TI  - Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG 
      Treatment Trials.
PG  - e1246-e1257
LID - 10.1200/OP.20.01096 [doi]
AB  - PURPOSE: Patient-reported outcomes may be associated with cancer outcomes. We 
      evaluated clinically significant fatigue (CSF), overall survival, adverse events 
      (AEs), and quality of life (QOL) during cancer treatment. METHODS: We compared 
      outcomes in four phase II or III chemotherapy trials, two advanced non-small-cell 
      lung cancer and two advanced hormone-refractory prostate cancer, with or without 
      baseline CSF. CSF was defined as a rating of two or greater on the Functional 
      Assessment of Cancer Therapy fatigue question or a European Organization for 
      Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 fatigue 
      symptom score of 50% or greater. Survival was compared according to CSF using 
      Kaplan-Meier estimates and Cox regression models. Differences in AE rates by CSF 
      were assessed via chi-squared tests, and QOL changes from baseline to 3 months 
      via linear regression. RESULTS: Of 1,994 participants, 1,907 (median age 69 
      years, range: 32-91) had complete baseline QOL survey data, with 52% reporting 
      CSF at baseline. For the two hormone-refractory prostate cancer studies, baseline 
      CSF was associated with higher mortality rates, with adjusted hazard ratios of 
      (95% CI, P value) 1.32 (1.13 to 1.55, P < .001) and 1.31 (1.02 to 1.67, P = .03) 
      and with increased incidence of grade 3-5 constitutional (16.5% v 9.4%, P = .002; 
      13.9% v 6.3%, P = .002) and neurologic (11.7% v 6.1%, P = .006; 9.0% v 3.9%, P = 
      .01) AEs, respectively. Baseline CSF was associated with a higher mortality rate 
      in one non-small-cell lung cancer study: hazard ratio 1.44 and 1.04 to 2.00, P = 
      .03. CONCLUSION: Oncology trial participants with baseline CSF had poorer 
      survival and experienced more AEs than participants without CSF. This indicates 
      fatigue as an important baseline prognostic factor in oncology treatment trials.
FAU - Mo, Julia
AU  - Mo J
AUID- ORCID: 0000-0002-6850-2184
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      PA.
FAU - Darke, Amy K
AU  - Darke AK
AUID- ORCID: 0000-0002-9821-2065
AD  - SWOG Cancer Research Network Statistics and Data Management Center, Fred 
      Hutchinson Cancer Research Center, Seattle, WA.
FAU - Guthrie, Katherine A
AU  - Guthrie KA
AD  - SWOG Cancer Research Network Statistics and Data Management Center, Fred 
      Hutchinson Cancer Research Center, Seattle, WA.
FAU - Sloan, Jeff A
AU  - Sloan JA
AUID- ORCID: 0000-0002-3393-2387
AD  - Mayo Clinic, Rochester, MN.
FAU - Unger, Joseph M
AU  - Unger JM
AUID- ORCID: 0000-0002-5191-0317
AD  - SWOG Cancer Research Network Statistics and Data Management Center, Fred 
      Hutchinson Cancer Research Center, Seattle, WA.
FAU - Hershman, Dawn L
AU  - Hershman DL
AUID- ORCID: 0000-0001-8807-153X
AD  - Columbia University Medical Center, New York, NY.
FAU - O'Rourke, Mark
AU  - O'Rourke M
AUID- ORCID: 0000-0003-1707-6186
AD  - Center for Integrative Oncology and Survivorship, Greenville Health System, 
      Clemson, SC.
FAU - Bakitas, Marie
AU  - Bakitas M
AUID- ORCID: 0000-0002-2913-2053
AD  - School of Nursing, University of Alabama at Birmingham, Birmingham, AL.
FAU - Krouse, Robert S
AU  - Krouse RS
AUID- ORCID: 0000-0002-7176-461X
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      PA.
LA  - eng
GR  - U10 CA180819/CA/NCI NIH HHS/United States
GR  - U10 CA180888/CA/NCI NIH HHS/United States
GR  - UG1 CA189974/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210713
PL  - United States
TA  - JCO Oncol Pract
JT  - JCO oncology practice
JID - 101758685
SB  - IM
MH  - Aged
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Fatigue
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - *Lung Neoplasms/drug therapy
MH  - Male
MH  - Quality of Life
PMC - PMC8360454
COIS- Dawn L. HershmanConsulting or Advisory Role: AIM Specialty HealthNo other 
      potential conflicts of interest were reported.
EDAT- 2021/07/14 06:00
MHDA- 2021/11/03 06:00
PMCR- 2022/08/01
CRDT- 2021/07/13 17:14
PHST- 2021/07/14 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/07/13 17:14 [entrez]
PHST- 2022/08/01 00:00 [pmc-release]
AID - OP.20.01096 [pii]
AID - 10.1200/OP.20.01096 [doi]
PST - ppublish
SO  - JCO Oncol Pract. 2021 Aug;17(8):e1246-e1257. doi: 10.1200/OP.20.01096. Epub 2021 
      Jul 13.